Company news

Argent Biopharma Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ArtemiC receives Indian importation and sales approval

January 6, 2022

ArtemiC Long COVID Syndrome Clinical Study Commenced

December 20, 2021

UK Capital Raising Completed

December 1, 2021

Production Completed of A$1M ArtemiC Order from SPC

November 24, 2021

US Supply and Distribution Agreement Update

November 22, 2021

Malta cimetra production facility update

November 2, 2021

Cimetra dose finding study approval

November 1, 2021

Response to ASX Query Letter

October 15, 2021

AMC inc. places US$3M CimetrA purchase order

October 6, 2021

First order received under US supply agreement

September 29, 2021

Artemic eu sale approval and clinical trial update

September 15, 2021

Uk import permit granted for cannepil

September 13, 2021

Cimetra import approval granted for india

September 3, 2021

MGC pharma executes US$24M US supply agreement

August 26, 2021

Patent application lodged for novel drug delivery system

July 15, 2021

1St patient recruited into CimetrA phase 3 clinical trial

July 12, 2021

Cannepil available for free dispensing in ireland

June 14, 2021

MGC pharma 2021 clinical trials program update

May 24, 2021

Cimetra patent submitted to european ip office

May 17, 2021

Further findings on ArtemiC as anti-inflammatory agent

May 7, 2021

$1M order for ArtemiC Rescue from swiss PharmaCan

May 3, 2021

ArtemiC submitted to Health Canada

April 28, 2021

March quarterly activity and cashflow report

April 26, 2021

MGC pharma to acquire medical research company MediCaNL

April 21, 2021

Investor presentation

April 9, 2021

Mxc completes first artemic order, march qtr record revenue

April 6, 2021

Ethics Committee Approval Granted Phase III Clinical Trial

March 22, 2021

SwissPharmaCan AG increases initial purchase order

March 2, 2021

MGC Pharma first medicinal cannabis company to list on LSE

February 3, 2021

MGC Pharma Investor Presentation

February 1, 2021

December Quarterly Activity and Cashflow Report

January 22, 2021

ArtemiC Phase II Clinical Trial Results

December 14, 2020

Prospectus

November 23, 2020

Mgc pharma completes acquisition of telehealth platform mcc

November 22, 2020

Further successful results from glioblastoma research

November 16, 2020

Completion of phase II clinical trial on COVID-19 patients

November 4, 2020

September Quarterly Activity and Cashflow Report

October 26, 2020

Mgc pharma delivers record consecutive weekly sales growth

October 19, 2020

Artemic histology on rats confirm no pathological impact

October 14, 2020

First high thc products shipped direct to Brazil patients

October 11, 2020

Mgc pharma launches cannepil app

October 6, 2020

Update on ArtemiC phase II trial on COVID-19 patients

September 28, 2020

Mxc welcomes new fca guidance for cannabis sector in the uk

September 20, 2020

Mxc well positioned for tga down-schedule of cbd products

September 13, 2020

$15M finance facility to fund revenue growth for key markets

September 10, 2020

Appendix 4E and Preliminary Unaudited Financial Report

August 31, 2020

Jv to be established for registration of artemic in russia

August 24, 2020

COVID-19 Interim Trial Results Meet All Primary Objectives

August 20, 2020

Uk distribution agreement signed for mgc pharma medicines

August 14, 2020

Study confirms effectiveness of artemic on human immune cell

August 6, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 10 decks. Every deck is listed under its year.